PDCD1 and melanoma: Pembrolizumab and Nivolumb, the most commonly used monoclonal PD-1 antibodies approved by USFDA, have been widely used for melanoma as well as non-small cell lung cancer (Robert et al., 2015; Reck et al., 2016).